Figure 2 | Scientific Reports

Figure 2

From: A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19

Figure 2

Effect of TM5614 or placebo evaluated by the total oxygen score from Day 1 to Day 14 (randomized, double-blind, placebo-controlled study). In the hospitalized patients with early pneumonia who were not receiving oxygen, the total oxygenation scale from Day 1 to Day 14 is marginally lower in the TM5614 group than in the placebo group (p = 0.07). This is not the case in patients receiving oxygen (p = 0.75).

Back to article page